Sogen Data · Datasets · 数据专题
神经母细胞瘤复发轴数据集锦
单细胞 · bulk 转录组
本专题承自 Sogen Data 数据整理体系,逐条人工复核,附研究设计、样本量、平台与 GEO/PubMed 直达链接。
人源单细胞
Human · Single-cell
-
01 GSE331214 对10名高危神经母细胞瘤患儿在诊断(Dx)、化疗后延迟肿瘤切除(Rx)和复发(Rel)阶段的肿瘤组织进行纵向单细胞转录组分析,以识别导致治疗耐药的基因和通路。从26个样本中获取了152,366个单细胞,其中80,678个为恶性交感神经细胞。通过患者特异性伪时间分析和轨迹分析,研究了恶性细胞对化疗的反应,并鉴定了如STMN1和ALYREF等上调的基因。进一步分析细胞轨迹,发现Hedgehog信号通路可能与化疗耐药相关,且可能来源于肿瘤内驻留的雪旺细胞。Hedgehog抑制剂在体外和体内实验中恢复了化疗敏感性。化疗后肿瘤微环境显示蛋白聚糖SRGN富集,提示其为免疫治疗新靶点。
设计对10名高危神经母细胞瘤患儿在诊断(Dx)、化疗后延迟肿瘤切除(Rx)和复发(Rel)阶段的肿瘤组织进行纵向单细胞转录组分析,以识别导致治疗耐药的基因和通路。从26个样本中获取了152,366个单细胞,其中80,678个为恶性交感神经细胞。通过患者特异性伪时间分析和轨迹分析,研究了恶性细胞对化疗的反应,并鉴定了如STMN1和ALYREF等上调的基因。进一步分析细胞轨迹,发现Hedgehog信号通路可能与化疗耐药相关,且可能来源于肿瘤内驻留的雪旺细胞。Hedgehog抑制剂在体外和体内实验中恢复了化疗敏感性。化疗后肿瘤微环境显示蛋白聚糖SRGN富集,提示其为免疫治疗新靶点。
摘要Minor drug-resistant populations emerge during treatment in cancers such as neuroblastoma and later drive relapse. There are no reliable methods for tracking or molecularly defining the cells that escape therapy or tailored therapeutic strategies to eradicate them. We generated longitudinal single cell transcriptomes of tumour tissues taken at diagnosis (Dx), at delayed tumour resection after chemotherapy (Rx), and at relapse (Rel), from 10 children uniformly treated for high-risk neuroblastoma, to define genes and pathways causing treatment resistance that may be therapeutically targeted. Among transcriptomes from 26 samples containing 152,366 single cells, we identified 80,678 malignant sympathetic single cells. Patient-specific pseudotime and trajectory analyses of malignant cell responses to chemotherapy revealed some gene candidates such as STMN1 and ALYREF, upregulated in response to chemotherapy. Knockdown of these genes in human neuroblastoma cell lines sensitised cells to chemotherapy. Pathway-level analyses of cell trajectories highlighted Hedgehog signalling as a novel mechanism of chemoresistance, possibly emanating from tumour-resident Schwann cells. Hedgehog inhibitors restored sensitivity to chemotherapy in vitro and in vivo. The tumor microenvironment following chemotherapy identified enrichment of the pro-inflammatory proteoglycan serglycin (SRGN) as a novel immunotherapy target. Thus, a longitudinal single cell transcriptomic diagnostic of chemo-resistance in neuroblastoma can reveal therapeutic targets.
-
02 GSE147766 对19例人类神经母细胞瘤复发样本进行单细胞RNA测序,结合多重免疫组化和生存分析,并与正常胎儿肾上腺单细胞RNA测序数据对比,分析肿瘤组织与正常组织的免疫细胞状态变化。
设计对19例人类神经母细胞瘤复发样本进行单细胞RNA测序,结合多重免疫组化和生存分析,并与正常胎儿肾上腺单细胞RNA测序数据对比,分析肿瘤组织与正常组织的免疫细胞状态变化。
摘要Our current knowledge of the different immune cells in neuroblastoma is based on in vitro and in vivo studies mainly focusing on a single cell type. Importantly, different studies have conveyed conflicting results. Moreover, a comprehensive immune cell overview at the single-cell level is still missing and understanding the complete immune cell composition of neuroblastoma will be crucial for the development of novel immunotherapeutics against the disease. In this study, we performed single-cell RNA-sequencing on nineteen human neuroblastoma samples coupled with multiplex immunohistochemistry and survival analysis using additional datasets to provide a comprehensive cellular and molecular immune cell landscape of human neuroblastoma. Further, we contrasted our data with single-cell RNA-sequencing data from normal fetal adrenal gland to characterize cell-state changes from normal tissue to cancerous neuroblastoma. Our analysis revealed 27 immune cell subtypes including distinct subpopulations of myeloid, NK, B and T cells not identified in neuroblastoma before. Several immune cell subtypes demonstrated a survival benefit such as inflammatory monocytes, tumor associated macrophages, various T cell populations, and Active NK cells. Furthermore, in contrast to adult cancers and previous neuroblastoma studies, we demonstrated an increase in inflammatory monocyte cell-state when contrasting normal and tumor tissue, while we do not observe differences in cytotoxicity and exhaustion score for cytotoxic T cells, nor in Treg activity. Finally, we performed a systemic receptor-ligand interaction analysis between tumor, stroma and immune cells, where we showed the neuroblastoma tumor microenvironment is highly complex and strongly correlated to survival. In addition, we highlighted several interactions that we suggest to be tested in future studies as a therapeutic option in human neuroblastoma. Taken together, our study significantly adds to the in depth understanding of the immune cell landscape, the complexity of the tumor microenvironment and it provides a resource for the development of novel immunotherapeutics for neuroblastoma.
人源bulk 转录组
Human · Bulk RNA-seq
-
01 GSE211653 研究对象为神经母细胞瘤复发样本,采用总RNA作为被测材料,根据 telomere maintenance mechanisms (TMM) 分型分为 TEL[+]、ALT[+]、TMM[-] 和 ambiguous 四组,通过高通量 RNA 测序进行表达谱分析和 TERRA 表达检测,比较不同 TMM 分型样本的基因表达差异。
设计研究对象为神经母细胞瘤复发样本,采用总RNA作为被测材料,根据 telomere maintenance mechanisms (TMM) 分型分为 TEL[+]、ALT[+]、TMM[-] 和 ambiguous 四组,通过高通量 RNA 测序进行表达谱分析和 TERRA 表达检测,比较不同 TMM 分型样本的基因表达差异。
摘要Telomere maintenance mechanisms (TMM) are a hallmark of high-risk neuroblastoma, and are conferred by activation of telomerase or alternative lengthening of telomeres (ALT). However, detection of TMM is not yet part of the clinical routine, and consensus on TMM detection, especially on ALT assessment, remains to be achieved. Based on our results we here propose a workflow to reliably detect TMM in neuroblastoma. We show that unambiguous classification is feasible following a stepwise approach that determines both, activation of telomerase and ALT. The workflow proposed in this study can be used in clinical routine and provides a framework to systematically evaluate telomere maintenance mechanisms in risk stratification and treatment allocation of neuroblastoma patients.
-
02 GSE65303 对复发神经母细胞瘤样本与术前肿瘤样本及对应正常样本进行基因表达分析,比较三组间差异。研究对象为人类肿瘤组织,采用Agilent 4x44k定制芯片检测总RNA表达,样本按复发状态与是否治疗分组,每组样本数按总单位数与组数估计。

课题合作 · 扫码加微信
bioinformaticsboy